Elimination Half-Lives Vary by Compound
PFAS compounds are eliminated from the human body primarily through urine, and to a lesser extent through sweat, feces, and breast milk. The rate of elimination varies considerably between compounds. PFOA has an estimated mean serum elimination half-life of approximately 3.8 years in humans — meaning that without re-exposure, blood PFOA levels would fall to half their starting concentration over that period. PFOS has a longer half-life of approximately 5 years. Short-chain compounds like PFBS are eliminated much more quickly, with half-lives measured in days to weeks.
Protein Binding in Blood
PFAS accumulation in blood serum is driven by binding to serum proteins, particularly albumin and lipoproteins. This protein binding explains why PFAS does not accumulate primarily in adipose tissue the way many other persistent organic pollutants do — PFAS follows protein distribution rather than fat distribution in the body. The liver and kidney are secondary accumulation sites due to the roles of these organs in PFAS processing and elimination.
Body Burden Reduction After Exposure Cessation
Studies of communities where PFAS-contaminated drinking water was replaced with clean water have documented gradual decline in serum PFAS levels following the change. Research on the Parkersburg, West Virginia community and the Camp Lejeune military base population shows that serum PFAS levels fall predictably after contaminated water exposure ends, following exponential decay curves consistent with measured half-lives. Continued exposure through other routes — PFAS-containing foods, consumer products — slows the decline.
Implications for Health Monitoring
Because PFAS persists in the body for years after exposure ends, health monitoring programs in PFAS-affected communities continue to find elevated serum levels even years after water treatment improvements. Long-term cancer and health outcome surveillance is warranted for communities with documented high PFAS exposure histories, as health effects from past peak exposures may manifest over decades. Serum PFAS testing provides a useful biomarker for assessing historical exposure and evaluating the effectiveness of exposure reduction interventions.